Company · BMRN
BioMarin Pharmaceutical Inc.
Name as listed on its exchange; filed with the SEC as BIOMARIN PHARMACEUTICAL INC.
Nasdaq's symbol directory lists BMRN on Nasdaq as “BioMarin Pharmaceutical Inc. - Common Stock”.
In the 12 months to Nov 8, 2026: insiders sold on 1 occasion ($1.2M); 1 filing by holders of 5% or more; 5 company reports (Form 8-K, since May 26, 2026).
All insider filings at the SEC · Appeared in No. 8
Insider trades · SEC Form 4
Those inside the hall
Open-market purchases and sales only. Legs one person filed for one day are combined.
Who traded
- Davis George Eric, EVP, Chief Legal Officer sold $1.2M
Every trade (1)
- SELLDavis George Eric, EVP, Chief Legal Officer sold $1.2M
Large holders · SEC Schedules 13D and 13G
Five percent and over
Anyone who comes to hold more than 5% of a company's voting shares must tell the SEC. A Schedule 13D is filed by a holder who may seek to influence the company; a 13G by one who states it is a passive investor. An amendment updates an earlier filing, and a stake reported as 0% means the holder says it has sold all, or nearly all, of its shares. Every recent 13D and 13G
- BlackRock, Inc. 10%
Company reports · SEC Form 8-K
In its own words
Current reports the company filed with the SEC; most items are due within four business days of the event. Each line lists the report's items by the SEC's own titles; the filing says what happened. Reports collected since May 26, 2026; every 8-K at the SEC.
- Results of operations and financial condition Nov 2, 2026
- Results of operations and financial condition Oct 6, 2026
- Entry into a material definitive agreement Sep 30, 2026
- Other events Sep 15, 2026
- Departure or appointment of directors or officers Sep 14, 2026
Sources: SEC EDGAR (Forms 4, 144 and 8-K) and STOCK Act periodic transaction reports. Filings can be late, amended or wrong at the source; see methodology.